Mela provided no explanation for Steinhart’s departure, which took effect at the end of last year. Steinhart had been Mela’s CFO since 2006 and the search for a replacement is underway.
Board members Anne Egger, Mark Fabiani and Mindy Meads also stepped down from their roles, due to "other professional commitments and a desire to streamline the board to better reflect the company’s current size." Meads, in particular, was recently named CEO of retailer Calypso St. Barth.
The company bolstered the board back up to 7 total members with the addition of venture capitalist Jeff O’Donnell, the managing director of BioStar Ventures. O’Donnell has served for 10 years as president & CEO of medical device firm PhotoMedex (NSDQ:PHMD), according to a press release.
"Jeff’s first-hand knowledge of medical devices as well as selling capital equipment into the dermatology field will be of great value to MELA Sciences," chairman Robert Coradini said in prepared remarks. "He also brings global expertise that will broaden our strategic thinking on ways to leverage our technology and grow the company."
MELA has been restructuring for some time now, recently hiring former Johnson & Johnson (NYSE:JNJ) group chairman Rose Crane as CEO in Nov. She joined on after longtime CEO Joseph Gulfo resigned his post after 9 years.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.